Sotatercept in Children with Pulmonary Hypertension—A Narrative Review
Children · 28.03.2026 · 13 (4) · 465
DOI: 10.3390/children13040465 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Children, online erschienen am 28.03.2026. Verfasst von Johanna Schulz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Cardiology, Children's Heart Clinic, University Heart & Vascular Center Hamburg, Martinistraße 52, 20246 Hamburg, Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background/Objectives: Pulmonary arterial hypertension (PAH) is a rare but life-threatening disease that presents particular therapeutic challenges in children. It is characterized by pulmonary vasoconstriction and vascular remodeling, leading to right ventricular strain and eventually right heart failure. Although advances in pharmacotherapy have improved outcomes, treatment options remain limited. This review aims to evaluate the potential role of sotatercept, a novel fusion protein recently approved for adult PAH, and to assess the translatability of adult data to the pediatric population.
Methods
A narrative synthesis of preclinical studies and randomized controlled trials was conducted to summarize the current evidence on sotatercept. In addition, pathophysiological, developmental, and therapeutic differences between adult and pediatric PAH were critically examined to assess relevance and applicability to younger patients.
Results
Clinical trials in adults (PULSAR, STELLAR, ZENITH, HYPERION) confirm sotatercept’s efficacy on background therapy, with significant reductions in pulmonary vascular resistance, improvements in 6 min walk distance, enhanced right ventricular function, and risk reductions in clinical worsening events. However, extrapolation to pediatric PAH faces challenges including etiological differences (e.g., PAH-CHD predominance, PPHN in infants), age-inappropriate endpoints (e.g., 6MWD infeasible in young children), variable growth-related pharmacokinetics, and compensatory RV physiology delaying overt failure. Safety concerns are manageable in adults but raise pediatric-specific alarms: activin inhibition’s theoretical tumorigenic potential (dual tumor suppressor/promoter role), pubertal/fertility disruption (FSH suppression, gonadal maturation delay), and skeletal growth interference—unproven clinically yet demanding long-term monitoring. The ongoing MOONBEAM trial will provide initial pharmacokinetic/safety data in children.
Conclusions
Sotatercept represents a promising, first-in-class therapeutic option for PAH with the potential to transform disease management. Nevertheless, dedicated pediatric studies are crucial to confirm safety, efficacy, and appropriate dosing and to define its role in the long-term treatment of children with PAH.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Cardiology, Children's Heart Clinic, University Heart & Vascular Center Hamburg, Martinistraße 52, 20246 Hamburg, Germany.
- Division of Respiratory Medicine, Department of Internal Medicine II, University Medical Centre Hamburg-Eppendorf Hamburg, Martinistraße 52, 20246 Hamburg, Germany.
ORCID-Profile: Johanna Schulz, Veronika C Stark, Rainer Kozlik-Feldmann, Thomas S Mir, Jakob Olfe
Zitieren
APA
Schulz, J., Stark, V. C., Harbaum, L., Kozlik-Feldmann, R., Mir, T. S., Stute, F., & Olfe, J. (2026). Sotatercept in Children with Pulmonary Hypertension—A Narrative Review. Children, 13(4), 465. https://doi.org/10.3390/children13040465
Vancouver
Schulz J, Stark VC, Harbaum L, Kozlik-Feldmann R, Mir TS, Stute F, et al. Sotatercept in Children with Pulmonary Hypertension—A Narrative Review. Children. 2026;13(4):465. doi:10.3390/children13040465
BibTeX
@article{Schulz2026,
author = {Schulz, Johanna and Stark, Veronika C and Harbaum, Lars and Kozlik-Feldmann, Rainer and Mir, Thomas S and Stute, Fridrike and Olfe, Jakob},
title = {Sotatercept in Children with Pulmonary Hypertension—A Narrative Review},
journal = {Children},
year = {2026},
volume = {13},
number = {4},
pages = {465},
doi = {10.3390/children13040465}
}
EUVIMED